Proteologics has anti-viral drug discovery programs based on proprietary research of host-protein ubiquitin-ligase drug targets shown to be essential for the HIV life cycle. Proteologics strategy is to target human pathways evolutionarily required for viral biogenesis consequently preventing completion of the viral life cycle in human cells. This new approach allows Proteologics to develop new drugs that are expected to be more effective than current therapies against the problematic emergence of viral resistance.
Avishai Levy, CEO and president of Proteologics, said: “The granting of broad substance-of-matter claims for therapeutic siRNA constructs relating to our antiviral drug discovery program provides further reassurance and increases our value proposition.”